system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Animals, Cardiotonic Agents, Heart, Lipopolysaccharides, Mice, Mice, Inbred C57BL, Myocardium, Nitric Oxide Synthase Type II, Nitric Oxide Synthase Type III, Proto-Oncogene Proteins c-bcl-2, Quercetin.
user
Does [ Quercetin protect against lipopolysaccharide-induced cardiac injury in mice ]? Context: To evaluate the protective effect of quercetin against lipopolysaccharide (LPS)-induced cardiac injury in mice. C57BL/6J mice were randomized into 4 groups to receive intraperitoneal injection of saline (negative control) or LPS (20 mg/kg), or fed with quercetin (100 mg/kg for 7 days) with or without subsequent LPS injection (quercetin+LPS group and quercetin control group, respectively). Six hour after LPS injection, the mice were tested for cardiac function with an echocardiograph, and the protein expressions of Bax, Bcl-2, iNOS, and eNOS in the myocardium were evaluated with Western blotting; serum NO concentration was also measured. The survival of the mice within 5 days after LPS injection was recorded to draw the survival curve. Quercetin pretreatment significantly improved the cardiac function of LPS-challenged mice (P<0.05), and attenuated LPS-induced increment in myocardial iNOS expression and decrement in eNOS level. LPS significantly increased the myocardial Bax expression and slightly decreased Bcl-2 expression; quercetin pretreatment decreased Bax expression to the control level and significantly lowered Bax/Bcl-2 ratio as compared with the LPS group. Serum NO level was significantly increased by nearly 2.5 folds in LPS-challenged mice, but was markedly decreased with quercetin pretreatment (P<0.05). The 5-day survival rate of LPS-treated mice was 10%, which was increased to 45% in quercetin- pretreated mice (P<0.05).
assistant
Quercetin can alleviate LPS-induced cardiac dysfunctions in mice to increase their survival rate following LPS challenge. Final Decision: yes